What is XAIR's health score?

Beyond Air, Inc. (XAIR) has a TradeApes health score of 43 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is XAIR's estimated fair value?

Based on our 5-year discounted cash flow model, Beyond Air, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is XAIR undervalued or overvalued?

Our model currently rates XAIR as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for XAIR... Refresh in a moment for the full analysis.

Beyond Air, Inc. (XAIR)

Healthcare Inconclusive inconclusive weak

$0.41

Updated: 2026-06-06

TradeApes Score

Financial Strength

35 Weak

Operating Trend

40 Weak

Relative Value

60 Healthy

Capital Allocation

30 Weak

Risk

50 Mixed

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.